ImmunoScape presented new preclinical data at the AACR Annual Meeting 2026, highlighting the potential of its Seed and Boost™ platform in solid tumor immunotherapy.
Key highlights from the study:
Significant in vivo expansion of TCR-T cells using the Seed and Boost™ approach Durable anti-tumor activity, including 100% survival in a high tumor burden ovarian cancer model Strong tumor infiltration observed in pancreatic cancer models Evidence of sustained T-cell fitness and selective CD8+ expansion Potential to improve therapeutic efficacy while reducing manufacturing complexity and cost These results further support advancement of ImmunoScape’s WT1-targeted program, with a first-in-human investigator-initiated trial planned at a leading NCI Cancer Center in Autumn 2026.